FDA Approves Extended-Release Version Of Merck’s Diabetes Medication Janumet

Merck & Co. Feb. 2 announced that the Food and Drug Administration has approved an extended-release version of its diabetes drug Janumet.

Janumet XR combines sitagliptin with extended-release metformin, the Whitehouse Station, N.J.-based company said. FDA approved the drug as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Merck said Janumet XR provides a convenient once-daily treatment option for health care providers and patients who need to control their blood sugar.

The labeling for Janumet XR contains a boxed warning for lactic acidosis, a rare, but serious complication that can occur ...